shutterstock-133427033
SEBASTIAN KAULITZKI / SHUTTERSTOCK.COM
8 June 2016AmericasKene Gallois

Best practices for patenting antibodies

Despite the continuing efforts to harmonise patent practice in all countries, some differences persist. When it comes to technological domains like biotechnology, minor differences can yield a huge impact in the end. This is the case of antibody patentability. It is not news that the Brazilian practice is inspired by the European one, but most Brazilian practitioners will agree that it comes with several kinds of restrictions.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.
Americas
30 June 2026   Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.
Americas
25 June 2026   The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.